AsclepiX Therapeutics Overview

  • Status
  • Private
  • Latest Deal Type
  • Series A
  • Latest Deal Amount
  • $35M
Latest Deal Amount
  • Investors
  • 13

AsclepiX Therapeutics General Information

Description

Developer of biomimetic anti-angiogenic and anti-lymphangiogenic peptides designed to transform the treatment of retinal disease and cancer through the rapid clinical development of groundbreaking therapies. The company's peptides are used for indications in ophthalmology, oncology and for other angiogenesi and lymphangiogenesis-dependent diseases, enabling patients and doctors to better treat ocular ailments.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Other Pharmaceuticals and Biotechnology
Drug Delivery
Primary Office
  • 301 West 29th Street
  • Suite 2004
  • Baltimore, MD 21211
  • United States
+1 (610) 000-0000

AsclepiX Therapeutics Timeline

2017201820192020
Financing Round
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

AsclepiX Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC (Series A) 24-Jun-2020 $35M 0000 Completed Generating Revenue
6. Grant 01-Jan-2019 00000 Completed Generating Revenue
5. Grant 01-Jan-2017 00.00 Completed Generating Revenue
4. Grant 01-Sep-2015 00000 Completed Generating Revenue
3. Grant 24-Jul-2014 00.000 Completed Generating Revenue
2. Accelerator/Incubator 25-Jun-2014 Completed Generating Revenue
1. Grant 15-Jun-2013 $100K Completed Generating Revenue
To view AsclepiX Therapeutics’s complete valuation and funding history, request access »

AsclepiX Therapeutics Executive Team (5)

Name Title Board Seat Contact Info
Jordan Green Ph.D Co-Founder, Board Member, Chief Technology Advisor & Chief Technology Officer
Aleksander Popel Ph.D Co-Founder, Board Member & Chief Scientific Officer
Theresa Heah Chief Medical Officer
Steven Altschuler MD Chairman
To view AsclepiX Therapeutics’s complete executive team members history, request access »

AsclepiX Therapeutics Board Members (7)

Name Representing Role Since
Ben Askew Ph.D Self Board Member 000 0000
Christopher Garabedian Perceptive Advisors Board Member 000 0000
Joshua Barer Barer & Son Capital Board Member 000 0000
Kevin Slawin MD Self Chief Executive Officer & Board Member 000 0000
Sapna Srivastava Ph.D Self Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »

AsclepiX Therapeutics Investors (13)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Barer & Son Capital Venture Capital Minority 000 0000 000000 0
Hibiscus Capital Management Corporate Venture Capital Minority 000 0000 000000 0
Perceptive Advisors Hedge Fund Minority 000 0000 000000 0
Piedmont Capital Partners Merchant Banking Firm 000 0000 000000 0
Rapha Capital Management Corporation 000 0000 000000 0
You’re viewing 5 of 13 investors. Get the full list »